TY - JOUR
T1 - The molecular biology of peritoneal metastatic disease
AU - Bootsma, Sanne
AU - Bijlsma, Maarten F.
AU - Vermeulen, Louis
N1 - Funding Information:
The authors would like to thank Prof. Dr. I.H.J.T. de Hingh for providing Fig 1A. This work is supported by Oncode Institute, The New York Stem Cell Foundation, grants from the European Research Council (ERC-CoG 101045612 - NIMICRY) and ZonMw (Vici 09-15018-21-10029) to LV and KWF (13435) to MFB. LV is a New York Stem Cell Foundation—Robertson Investigator.
Funding Information:
The authors would like to thank Prof. Dr. I.H.J.T. de Hingh for providing Fig 1A . This work is supported by Oncode Institute, The New York Stem Cell Foundation, grants from the European Research Council (ERC‐CoG 101045612 ‐ NIMICRY) and ZonMw (Vici 09‐15018‐21‐10029) to LV and KWF (13435) to MFB. LV is a New York Stem Cell Foundation—Robertson Investigator.
Funding Information:
LV received consultancy fees from Bayer, MSD, Genentech, Servier and Pierre Fabre, but these had no relation to the content of this publication. MFB has received research funding from Celgene, Lead Pharma, and Frame Therapeutics and has received consultancy fees from Servier. SB declares no conflict of interest.
Publisher Copyright:
© 2023 The Authors. Published under the terms of the CC BY 4.0 license.
PY - 2023/3/8
Y1 - 2023/3/8
N2 - Peritoneal metastases are a common form of tumor cell dissemination in gastrointestinal malignancies. Peritoneal metastatic disease (PMD) is associated with severe morbidity and resistance to currently employed therapies. Given the distinct route of dissemination compared with distant organ metastases, and the unique microenvironment of the peritoneal cavity, specific tumor cell characteristics are needed for the development of PMD. In this review, we provide an overview of the known histopathological, genomic, and transcriptomic features of PMD. We find that cancers representing the mesenchymal subtype are strongly associated with PMD in various malignancies. Furthermore, we discuss the peritoneal niche in which the metastatic cancer cells reside, including the critical role of the peritoneal immune system. Altogether, we show that PMD should be regarded as a distinct disease entity, that requires tailored treatment strategies.
AB - Peritoneal metastases are a common form of tumor cell dissemination in gastrointestinal malignancies. Peritoneal metastatic disease (PMD) is associated with severe morbidity and resistance to currently employed therapies. Given the distinct route of dissemination compared with distant organ metastases, and the unique microenvironment of the peritoneal cavity, specific tumor cell characteristics are needed for the development of PMD. In this review, we provide an overview of the known histopathological, genomic, and transcriptomic features of PMD. We find that cancers representing the mesenchymal subtype are strongly associated with PMD in various malignancies. Furthermore, we discuss the peritoneal niche in which the metastatic cancer cells reside, including the critical role of the peritoneal immune system. Altogether, we show that PMD should be regarded as a distinct disease entity, that requires tailored treatment strategies.
KW - gastrointestinal cancer
KW - metastasis
KW - peritoneum
KW - tumor biology
KW - tumor microenvironment
UR - https://www.scopus.com/pages/publications/85146821971
U2 - 10.15252/emmm.202215914
DO - 10.15252/emmm.202215914
M3 - Review article
C2 - 36700339
SN - 1757-4676
VL - 15
JO - EMBO molecular medicine
JF - EMBO molecular medicine
IS - 3
M1 - e15914
ER -
SDG 3 Good Health and Well-being